Konstantina Poulianiti
University of Thessaly
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Konstantina Poulianiti.
Inhalation Toxicology | 2013
Andreas D. Flouris; Maria S. Chorti; Konstantina Poulianiti; Athanasios Z. Jamurtas; Konstantinos Kostikas; Manolis Tzatzarakis; A. Wallace Hayes; Aristidis M. Tsatsakis; Yiannis Koutedakis
Abstract Context: Electronic cigarettes (e-cigarettes) are becoming increasingly popular yet their effects on health remain unknown. Objective: To conduct the first comprehensive and standardized assessment of the acute impact of active and passive e-cigarette smoking on serum cotinine and lung function, as compared to active and passive tobacco cigarette smoking. Materials and methods: Fifteen smokers (≥15 cigarettes/day; seven females; eight males) and 15 never-smokers (seven females; eight males) completed this repeated-measures controlled study. Smokers underwent a control session, an active tobacco cigarette (their favorite brand) smoking session and an active e-cigarette smoking session. Never-smokers underwent a control session, a passive tobacco cigarette smoking session and a passive e-cigarette smoking session. Serum cotinine, lung function, exhaled carbon monoxide and nitric oxide were assessed. The level of significance was set at p ≤ 0.001 to adjust for multiple comparisons. Results: e-Cigarettes and tobacco cigarettes generated similar (p > 0.001) effects on serum cotinine levels after active (60.6 ± 34.3 versus 61.3 ± 36.6 ng/ml) and passive (2.4 ± 0.9 versus 2.6 ± 0.6 ng/ml) smoking. Neither a brief session of active e-cigarette smoking (indicative: 3% reduction in FEV1/FVC) nor a 1 h passive e-cigarette smoking (indicative: 2.3% reduction in FEV1/FVC) significantly affected the lung function (p > 0.001). In contrast, active (indicative: 7.2% reduction in FEV1/FVC; p < 0.001) but not passive (indicative: 3.4% reduction in FEV1/FVC; p = 0.005) tobacco cigarette smoking undermined lung function. Conclusion: Regarding short-term usage, the studied e-cigarettes generate smaller changes in lung function but similar nicotinergic impact to tobacco cigarettes. Future research should target the health effects of long-term e-cigarette usage, including the effects of nicotine dosage.
Food and Chemical Toxicology | 2012
Andreas D. Flouris; Konstantina Poulianiti; Maria S. Chorti; Athanasios Z. Jamurtas; Dimitrios Kouretas; Emmanuel O. Owolabi; Manolis Tzatzarakis; Aristidis M. Tsatsakis; Yiannis Koutedakis
The World Health Organisation called for research assessing the safety of electronic cigarette (e-cigarette). We evaluated the acute effect of active and passive e-cigarette and tobacco cigarette smoking on complete blood count (CBC) markers in 15 smokers and 15 never-smokers, respectively. Smokers underwent a control session, an active tobacco cigarette smoking session, and an active e-cigarette smoking session. Never-smokers underwent a control session, a passive tobacco cigarette smoking session, and a passive e-cigarette smoking session. The results demonstrated that CBC indices remained unchanged during the control session and the active and passive e-cigarette smoking sessions (P>0.05). Active and passive tobacco cigarette smoking increased white blood cell, lymphocyte, and granulocyte counts for at least one hour in smokers and never smokers (P<0.05). It is concluded that acute active and passive smoking using the e-cigarettes tested in the current study does not influence CBC indices in smokers and never smokers, respectively. In contrast, acute active and passive tobacco cigarette smoking increase the secondary proteins of acute inflammatory load for at least one hour. More research is needed to evaluate chemical safety issues and other areas of consumer product safety of e-cigarettes, because the nicotine content in the liquids used may vary considerably.
Oxidative Medicine and Cellular Longevity | 2016
Konstantina Poulianiti; Antonia Kaltsatou; Georgia Mitrou; Athanasios Z. Jamurtas; Yiannis Koutedakis; Maria Maridaki; Ioannis Stefanidis; Giorgos K. Sakkas; Christina Karatzaferi
Patients with chronic kidney disease (CKD) experience imbalance between oxygen reactive species (ROS) production and antioxidant defenses leading to cell and tissue damage. However, it remains unclear at which stage of renal insufficiency the redox imbalance becomes more profound. The aim of this systematic review was to provide an update on recent advances in our understanding of how the redox status changes in the progression of renal disease from predialysis stages 1 to 4 to end stage 5 and whether the various treatments and dialysis modalities influence the redox balance. A systematic review was conducted searching PubMed and Scopus by using the Cochrane and PRISMA guidelines. In total, thirty-nine studies met the inclusion criteria and were reviewed. Even from an early stage, imbalance in redox status is evident and as the kidney function worsens it becomes more profound. Hemodialysis therapy per se seems to negatively influence the redox status by the elevation of lipid peroxidation markers, protein carbonylation, and impairing erythrocyte antioxidant defense. However, other dialysis modalities do not so far appear to confer advantages. Supplementation with antioxidants might assist and should be considered as an early intervention to halt premature atherogenesis development at an early stage of CKD.
Toxicology Mechanisms and Methods | 2016
Konstantina Poulianiti; Christina Karatzaferi; Andreas D. Flouris; Ioannis G. Fatouros; Yiannis Koutedakis; Athanasios Z. Jamurtas
Abstract Context: It has been indicated that acute active and passive tobacco cigarette smoking may cause changes on redox status balance that may result in significant pathologies. However, no study has evaluated the effects of active and passive e-cigarette smoking on redox status of consumers. Objective: To examine the acute effects of active and passive e-cigarette and tobacco cigarette smoking on selected redox status markers. Methods: Using a randomized single-blind crossover design, 30 participants (15 smokers and 15 nonsmokers) were exposed to three different experimental conditions. Smokers underwent a control session, an active tobacco cigarette smoking session (smoked 2 cigarettes within 30-min) and an active e-cigarette smoking session (smoked a pre-determined number of puffs within 30-min using a liquid with 11 ng/ml nicotine). Similarly, nonsmokers underwent a control session, a passive tobacco cigarette smoking session (exposure of 1 h to 23 ± 1 ppm of CO in a 60 m3 environmental chamber) and a passive e-cigarette smoking session (exposure of 1 h to air enriched with pre- determined number of puffs in a 60 m3 environmental chamber). Total antioxidant capacity (TAC), catalase activity (CAT) and reduced glutathione (GSH) were assessed in participants’ blood prior to, immediately after, and 1-h post-exposure. Results: TAC, CAT and GSH remained similar to baseline levels immediately after and 1-h-post exposure (p > 0.05) in all trials. Conclusions: Tobacco and e-cigarette smoking exposure do not acutely alter the response of the antioxidant system, neither under active nor passive smoking conditions. Overall, there is not distinction between tobacco and e-cigarette active and passive smoking effects on specific redox status indices.
Toxicology Letters | 2012
Maria S. Chorti; Konstantina Poulianiti; Athanasios Z. Jamurtas; Konstantinos Kostikas; Manolis Tzatzarakis; Dionysios Vynias; Yiannis Koutedakis; Andreas D. Flouris; Aristidis M. Tsatsakis
Toxicology Letters | 2013
Manolis Tzatzarakis; Kyriakos I. Tsitoglou; Maria S. Chorti; Konstantina Poulianiti; Athanasios Z. Jamurtas; Yiannis Koutedakis; Andreas D. Flouris; Kyriakakis Michalis; Tsatsakis Aristidis
Frontiers in Physiology | 2015
Antonia Kaltsatou; Giorgos K. Sakkas; Konstantina Poulianiti; Yiannis Koutedakis; Konstantinos Tepetes; Grigorios Christodoulidis; Ioannis Stefanidis; Christina Karatzaferi
Toxicology Letters | 2012
Dimitrios Kouretas; Konstantina Poulianiti; Maria S. Chorti; Athanasios Z. Jamurtas; Konstantinos Kostikas; Manolis Tzatzarakis; Yiannis Koutedakis; Andreas D. Flouris; Aristidis M. Tsatsakis
Current Pharmaceutical Design | 2016
Antonia Kaltsatou; Christina Karatzaferi; Georgia Mitrou; Konstantina Poulianiti; Giorgos K. Sakkas
Industrial Health | 2018
Konstantina Poulianiti; George Havenith; Andreas D. Flouris